Company logo

KTTA - Pasithea Therapeutics Corp.

NASDAQ -> Healthcare -> Biotechnology
Miami Beach, United States
Type: Equity

KTTA price evolution
KTTA
(in millions $) 30 Oct 2023 30 Jul 2023 1 May 2023 31 Jan 2023
Current assets
Cash $33.15
Short term investments
Net receivables $0.1 $0.12 $0.3
Inventory
Total current assets $20.77 $28.04 $31.11 $34.08
Long term investments
Property, plant & equipment $0.52 $0.59 $0.64 $1.25
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $30.66 $38.15 $42.04 $45.18
Current liabilities
Accounts payable $1.87 $1.93 $1.45 $1.61
Deferred revenue
Short long term debt
Total current liabilities $2.04 $2.23 $2.12 $1.88
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $2.28 $2.56 $2.91 $2.68
Shareholders' equity
Retained earnings -$30.27 -$26.66 -$22.89 -$19.36
Other shareholder equity -$0.01 -$0 -$0
Total shareholder equity
(in millions $) 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash $33.15
Short term investments
Net receivables $0.3
Inventory
Total current assets $34.08 $53.3 $0.25
Long term investments
Property, plant & equipment $1.25 $0.02
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $45.18 $53.32 $0.25
Current liabilities
Accounts payable $1.61 $0.45 $0.01
Deferred revenue
Short long term debt
Total current liabilities $1.88 $0.45 $0.01
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $2.68 $1.9 $0.01
Shareholders' equity
Retained earnings -$19.36 -$2.21 -$0.04
Other shareholder equity -$0 -$0.01
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue $0.22 $0.01 $0.01 $0.02
Cost of revenue
Gross Profit $0.13 -$0
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $4.38 $3.08 $2.41 $1.95
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense -$0.34 $0.42 $0.79 $2.59
Net income
Net income -$4.59 -$2.66 -$1.57 $0.63
Income (for common shares)
(in millions $) 31 Jan 2022 31 Jan 2021
Revenue
Total revenue $0.02
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $4.5
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $2.33
Net income
Net income -$2.17
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.31 -$0.08 -$0.11 -$0.02
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $55.93
Effect of exchange rate -$0.12 -$0.05 -$0.01
Change in cash and equivalents -$10.57 -$5.03 -$2.65 $52.73
(in millions $) 31 Jan 2022 31 Jan 2021
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.02
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $55.93
Effect of exchange rate -$0.01
Change in cash and equivalents $52.73
Fundamentals
Market cap $151.09M
Enterprise value N/A
Shares outstanding 20.84M
Revenue $262.19K
EBITDA N/A
EBIT N/A
Net Income -$8.18M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -18.46
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 576.26
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.39
ROA -20.98%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 10.18
Quick ratio N/A